Humana AB

Humana AB has a debt-to-equity ratio of 1.41, indicating a moderate reliance on debt financing, and a current ratio of 0.67, suggesting potential liquidity constraints in the short term. The company's liquidity position is assessed as medium risk, with net cash being negative after subtracting total debt. In terms of profitability, the company's return on equity (ROE) is 7.61%, which is below the industry median of 12.3%, and its return on assets (ROA) is 2.52%, also below the industry median of 4.1%. These figures suggest that the company is underperforming relative to its peers in terms of capital efficiency and asset utilization. Humana AB's revenue is concentrated in a few key markets, with the majority of its sales coming from Sweden and the United States. The company has not disclosed specific segment revenues, but its geographic exposure is heavily weighted toward these two regions. The company's growth trajectory is modest, with a projected revenue increase of 3.2% in the current fiscal year and 4.5% in the next fiscal year. This growth is driven by the continued commercialization of its oncology and rare disease products. Risk factors for Humana AB include its high debt load and limited liquidity, which could constrain its ability to invest in R&D or respond to market opportunities. The company's dilution risk is assessed as low, with no significant dilution expected in the near term. Recent events include the filing of its annual report, which disclosed the company's financial position and strategic priorities for the coming year. No major regulatory or legal issues were reported in the latest filings.